GLIPR1L2

Across TCGA pan-cancer cohorts, GLIPR1L2 mass-spec protein differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of GLIPR1L2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where GLIPR1L2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types GLIPR1L2 is over-expressed in tumor.

CCRCC are the cancer types where GLIPR1L2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GLIPR1L2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	+0.895	<.001	12	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 1 strongest of 1 lineages.

GLIPR1L2–CCRCC

Open the CCRCC breakdown →